- Home
- AUTL vs TMCI Comparison
AUTL vs TMCI Comparison
Compare AUTL & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- TMCI
- Stock Information
- Founded
- AUTL 2014
- TMCI 2014
- Country
- AUTL United Kingdom
- TMCI United States
- Employees
- AUTL N/A
- TMCI N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AUTL Health Care
- TMCI Health Care
- Exchange
- AUTL Nasdaq
- TMCI Nasdaq
- Market Cap
- AUTL 590.8M
- TMCI 649.1M
- IPO Year
- AUTL 2018
- TMCI 2021
- Fundamental
- Price
- AUTL $1.95
- TMCI $9.37
- Analyst Decision
- AUTL Strong Buy
- TMCI Hold
- Analyst Count
- AUTL 3
- TMCI 8
- Target Price
- AUTL $10.20
- TMCI $8.84
- AVG Volume (30 Days)
- AUTL 1.2M
- TMCI 413.1K
- Earning Date
- AUTL 03-13-2025
- TMCI 02-27-2025
- Dividend Yield
- AUTL N/A
- TMCI N/A
- EPS Growth
- AUTL N/A
- TMCI N/A
- EPS
- AUTL N/A
- TMCI N/A
- Revenue
- AUTL $10,091,000.00
- TMCI $202,861,000.00
- Revenue This Year
- AUTL $851.88
- TMCI $13.27
- Revenue Next Year
- AUTL $220.57
- TMCI $8.61
- P/E Ratio
- AUTL N/A
- TMCI N/A
- Revenue Growth
- AUTL 82.71
- TMCI 16.14
- 52 Week Low
- AUTL $1.87
- TMCI $3.92
- 52 Week High
- AUTL $6.63
- TMCI $14.82
- Technical
- Relative Strength Index (RSI)
- AUTL 37.49
- TMCI 47.42
- Support Level
- AUTL $1.92
- TMCI $9.69
- Resistance Level
- AUTL $2.15
- TMCI $10.30
- Average True Range (ATR)
- AUTL 0.12
- TMCI 0.45
- MACD
- AUTL 0.01
- TMCI -0.16
- Stochastic Oscillator
- AUTL 22.22
- TMCI 3.40
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.